

Zeal & Innovation in Medicine

Ref: ZLL/Compliance/LODR

BSE Limited, Compliance Department, P. J. Towers, Dalal Street, MUMBAI – 400 001 Company Code – 541400

Dear Sirs,

Sub: Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 – Grant of US Patent to ZIM Labs.

Pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015, we would like to inform you that the company has been issued a new U.S. patent for the invention of "Pharmaceutical Microemulsions Immobilized In A Thin Polymer Matrix And Methods Of Making Same". The technology has been developed by the company and registered in the United States Patent and Trademark Office under the number US 10, 660,862 B2.

Brief description about the technology for which Patent has been granted by the United States Patent and Trademark Office

The invention pertains to stable microemulsions immobilized in a thin polymer matrix compositions and a process of making the same. In particular, the invention pertains to stable pharmaceutical microemulsion by immobilization in the polymer matrix. Microemulsions are well-known vehicles for drug delivery that can be used to enhance penetration and absorption of active pharmaceutical ingredients from the site of administration. Controlling the release rate of drug, enhancing stability and taste masking are some more uses of microemulsions. Thin films are recently becoming very popular dosage form among special needs patient populations because of the patient convenience and therapeutic regimen compliance-related advantages. Thin-films can be given by topical, oral, buccal, sublingual, nasal, vaginal and rectal routes of administration. Immobilizing microemulsions into thin-film matrix will combine the advantages of both the delivery systems and forms a unique drug delivery system.

This technology will enable the company to deliver many large molecules and other molecules, that currently can be administered only by injectables, by non-invasive routes. With the addition of this technology, company's thin-film manufacturing capabilities have been strengthened.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Kindly take the intimation on record.

Yours faithfully, For ZIM LABORATORIES LIMITED

(Piyush Nikhade)

Company Secretary and Compliance Officer



ZIM LABORATORIES LIMITED

Date: 08.06.2020